Emerald Advisers LLC Buys 10,262 Shares of Nektar Therapeutics $NKTR

Posted by Stanley Muller on Jul 14th, 2026

Emerald Advisers LLC raised its stake in Nektar Therapeutics (NASDAQ:NKTR – Free Report) by 2.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 394,604 shares of the biopharmaceutical company’s stock after acquiring an additional 10,262 shares during the quarter. Emerald Advisers LLC owned about 1.17% of Nektar Therapeutics worth $28,392,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of NKTR. AQR Capital Management LLC increased its holdings in shares of Nektar Therapeutics by 336.9% in the first quarter. AQR Capital Management LLC now owns 3,640,851 shares of the biopharmaceutical company’s stock valued at $2,463,000 after purchasing an additional 2,807,595 shares in the last quarter. Farallon Capital Management LLC acquired a new position in Nektar Therapeutics during the 3rd quarter worth $45,008,000. Two Seas Capital LP bought a new position in Nektar Therapeutics in the 4th quarter valued at $31,506,000. Prosight Management LP bought a new position in Nektar Therapeutics in the 4th quarter valued at $23,450,000. Finally, Two Sigma Investments LP increased its stake in shares of Nektar Therapeutics by 446.9% in the 3rd quarter. Two Sigma Investments LP now owns 434,237 shares of the biopharmaceutical company’s stock valued at $24,708,000 after buying an additional 354,842 shares during the period. 75.88% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Jonathan Zalevsky sold 5,681 shares of the company’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $70.00, for a total value of $397,670.00. Following the completion of the sale, the insider directly owned 9,756 shares of the company’s stock, valued at $682,920. This represents a 36.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Howard W. Robin sold 10,000 shares of the stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $60.32, for a total transaction of $603,200.00. Following the completion of the sale, the chief executive officer owned 65,045 shares in the company, valued at $3,923,514.40. This represents a 13.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 21,862 shares of company stock worth $1,379,205 in the last three months. Insiders own 2.50% of the company’s stock.

Nektar Therapeutics Stock Performance

Shares of Nektar Therapeutics stock opened at $68.32 on Tuesday. The firm has a fifty day moving average of $67.35 and a two-hundred day moving average of $64.01. The stock has a market capitalization of $2.31 billion, a price-to-earnings ratio of -8.11 and a beta of 1.13. Nektar Therapeutics has a 52 week low of $21.02 and a 52 week high of $109.00.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.58) by ($0.24). Nektar Therapeutics had a negative net margin of 284.18% and a negative return on equity of 85.40%. The company had revenue of $10.86 million during the quarter, compared to analyst estimates of $10.69 million. As a group, research analysts forecast that Nektar Therapeutics will post -9.45 EPS for the current fiscal year.

Analyst Ratings Changes

NKTR has been the subject of a number of recent research reports. Wall Street Zen upgraded Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. BTIG Research lifted their price objective on Nektar Therapeutics from $151.00 to $178.00 and gave the stock a “buy” rating in a research report on Monday, April 20th. Citigroup lifted their price objective on Nektar Therapeutics from $123.00 to $151.00 and gave the stock a “buy” rating in a research report on Tuesday, April 21st. Piper Sandler boosted their price objective on Nektar Therapeutics from $105.00 to $192.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Finally, HC Wainwright upped their target price on shares of Nektar Therapeutics from $165.00 to $185.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $149.62.

Read Our Latest Report on NKTR

Nektar Therapeutics Company Profile

(Free Report)

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.